BioCentury
ARTICLE | Clinical News

PNT2258: Interim Phase II data

December 23, 2013 8:00 AM UTC

Interim data from 11 evaluable patients in an open-label, U.S. Phase II trial showed that 120 mg/m 2 IV PNT2258 on days 1-5 of a 21 day cycle led to an overall response rate (ORR) of 28%, including 2 complete responses and 1 partial response, plus 6 cases of stable disease. Of the evaluable patients, 5 had follicular lymphoma, 2 had diffuse large B cell lymphoma (DLBCL), 2 had mantle cell lymphoma (MCL) and 2 had chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL). PNT2258 was safe with no tumor lysis syndrome or major organ toxicities reported. The most common adverse events included nausea, chills, diarrhea, fever, tumor pain and vomiting. Data were presented at the American Society of Hematology meeting in New Orleans. ...